Neurocrine Biosciences
NBIX
#1377
Rank
S$19.66 B
Marketcap
S$194.24
Share price
-3.84%
Change (1 day)
7.61%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): S$8.95

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$8.99. In 2025 the company made an earnings per share (EPS) of S$6.22 an increase over its 2024 EPS that were of S$4.36.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$8.9543.98%
2025S$6.2242.6%
2024S$4.3633.07%
2023S$3.2857.76%
2022S$2.0869.47%
2021S$1.23-78.21%
2020S$5.62990%
2019S$0.5281.82%
2018S$0.28-113.5%
2017S-$2.100.62%
2016S-$2.0957.28%
2015S-$1.3325.61%
2014S-$1.0618.84%
2013S-$0.89-1085.71%
2012S$0.09030

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$0.92-89.81%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$7.55-16.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$39.85 343.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S-$0.26-102.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.62-129.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$6.68-25.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$9.74-208.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$1.97-78.06%๐Ÿ‡ฌ๐Ÿ‡ง UK